Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (1-10 of 413) with videos related to

Pageof 42
Sort By:
Current Oncology Reports|August 5, 2003
Randomized trials in oncology: a fertile ground for controversyMaurie Markman
Cancer|October 7, 2010
The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapyMaurie Markman
Oncology|November 6, 2010
A critical need to reconsider cancer trial eligibility requirementsMaurie Markman
Current Oncology Reports|August 17, 2010
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer managementMaurie Markman
Cancer Investigation|January 23, 2009
The myth of measurable disease in ovarian cancer: revisitedMaurie Markman
Oncology|March 25, 2011
Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trialMaurie Markman
Women'S Health (London, England)|January 10, 2018
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancerMaurie Markman
Current Oncology Reports|February 10, 2018
The Requirement for Increasingly Effective Societal Cancer Control EffortsMaurie Markman
Cancer|February 23, 2007
Effect of obesity on survival in epithelial ovarian cancerMaurie Markman
Cancer|February 22, 2007
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncologyMaurie Markman
Pageof 42

Showing results (1-10 of 413) with videos related to

Sort By:
Pageof 42
Current Oncology Reports|August 5, 2003
Randomized trials in oncology: a fertile ground for controversyMaurie Markman
Cancer|October 7, 2010
The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapyMaurie Markman
Oncology|November 6, 2010
A critical need to reconsider cancer trial eligibility requirementsMaurie Markman
Current Oncology Reports|August 17, 2010
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer managementMaurie Markman
Cancer Investigation|January 23, 2009
The myth of measurable disease in ovarian cancer: revisitedMaurie Markman
Oncology|March 25, 2011
Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trialMaurie Markman
Women'S Health (London, England)|January 10, 2018
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancerMaurie Markman
Current Oncology Reports|February 10, 2018
The Requirement for Increasingly Effective Societal Cancer Control EffortsMaurie Markman
Cancer|February 23, 2007
Effect of obesity on survival in epithelial ovarian cancerMaurie Markman
Cancer|February 22, 2007
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncologyMaurie Markman
Pageof 42